FDA-filed SPL labeling · retrieved through openFDA

Brimonidine

Brimonidine is an alpha-2 adrenergic agonist used in eye drop form to lower elevated eye pressure in open-angle glaucoma and ocular hypertension, to relieve eye redness, and in gel form to reduce facial redness from rosacea.

Brand names MirvasoLumifyAlphaganAlphagan PLUMIFY Redness Reliever Eye Drops +1 more
Drug classes ⓘ Adrenergic Alpha-agonists
Rx/OTC Forms 3 Routes Ophthalmic · Topical
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 21 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

At a glance
Linked label effectiveNov 24, 2025
Clinical labels in scope ⓘ21
AvailabilityRx/OTC
Earliest approval/marketing year ⓘ1996
FDA-listed product records ⓘ94
Boxed warningNone found in compared labels
How we combine label and product data →
✓No current FDA shortage listed · checked Sep 19, 2026
Other forms & routes:
Ophthalmic
⭐ Brimonidine at a glance The quick version — the full detail is in the Patient Information Guide below.
💊
HelloPharmacist Editorial Team Bottom Line
Brimonidine is a versatile medication: as an eye drop it lowers eye pressure in glaucoma and ocular hypertension, and as a gel it reduces facial redness from rosacea. The product and form matter a lot — dosing, uses, and risks differ between the eye drops and the gel, so always use the exact product your prescriber or the label specifies. Keep the gel away from children and do not use any form of brimonidine alongside MAO inhibitor medications.
How we write & review this content — our editorial policy →

📖 Brimonidine: Patient Information Guide

A plain-language walkthrough of Brimonidine — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.

🎯What it's used for▾

Brimonidine is available in two distinct forms — eye drops and a topical gel — with different approved uses for each.

  • Open-angle glaucoma and ocular hypertension (elevated eye pressure): Alphagan P, Brimonidine Tartrate Ophthalmic Solution, Brimonidine Tartrate, and Brimonidine ophthalmic drops are all indicated to reduce elevated intraocular pressure in these conditions.
  • Eye redness from minor irritation: LUMIFY Redness Reliever Eye Drops and Lumify Preservative Free Eye Drops are indicated to relieve redness of the eye due to minor eye irritations — this is a distinct, over-the-counter use.
  • Facial redness from rosacea: Mirvaso topical gel and Brimonidine topical gel (0.33%) are indicated for the topical treatment of persistent facial erythema (redness) of rosacea in adults 18 years and older.
⚙️How it works▾

Brimonidine selectively activates alpha-2 adrenergic receptors — specialized docking sites found on blood vessels and eye tissue. In the eye, this dual action reduces the amount of aqueous humor (the fluid the eye produces) and improves its drainage out of the eye, together lowering the pressure. On the skin, activating these receptors causes the small blood vessels to constrict, visibly reducing the facial redness of rosacea. The eye-pressure-lowering effect peaks about two hours after a dose, and at the doses used in eye drops, brimonidine has minimal effect on heart rate or lung function.

💊How it's taken▾

How and how often you use brimonidine depends entirely on the product prescribed or recommended for you — do not switch products or change dosing without guidance from your prescriber or pharmacist.

  • Eye drops for glaucoma/ocular hypertension (Alphagan P, Brimonidine Tartrate Ophthalmic Solution, and others): one drop in the affected eye(s) three times daily, spaced roughly 8 hours apart. If using more than one eye drop product, wait at least 5 minutes between them.
  • LUMIFY Redness Reliever Eye Drops: one drop in the affected eye(s) every 6–8 hours, no more than 4 times a day.
  • Lumify Preservative Free Eye Drops: one drop per use from a single-use vial; discard after use; no more than 4 times daily.
  • Brimonidine/Mirvaso topical gel for rosacea: applied once daily to the face.
🤒Side effects — in detail▾

Side effects vary depending on the product and form used.

  • With the topical gel: skin flushing, redness (erythema), burning sensation on the skin, contact dermatitis (skin irritation/rash), and skin warmth are the most common. Blurred vision and nasal congestion were also reported in trials.
  • With the eye drops: drowsiness and decreased alertness are especially common in young children — seen in the majority of children aged 2 to 6 in clinical studies.
  • Long-term use of the topical gel has been associated with flushing (10%), redness flares (8%), and in some cases, a rebound worsening of facial redness after stopping the gel.

Serious reactions — including very low blood pressure, slow heart rate, dizziness, or allergic reactions (swelling of the lips, tongue, or throat, hives) — have been reported, especially with the gel. Seek care promptly if these occur.

⚠️Warnings & precautions▾
  • Accidental ingestion by children is a medical emergency: Young children who swallowed brimonidine topical gel experienced life-threatening breathing problems, dangerously slow heart rate, extreme lethargy, and confusion. Keep the gel completely out of reach of children at all times.
  • Eye drops are contraindicated in infants and babies under 2 years old: Serious events including apnea (stopped breathing), coma, low blood pressure, and severe drowsiness have been reported in this age group.
  • Children aged 2–6 using the eye drops have a high rate of somnolence (extreme sleepiness) — monitor closely.
  • Cardiovascular caution: Brimonidine can lower blood pressure. Use the topical gel with extra care if you have severe or unstable heart disease. Postmarketing reports have documented low blood pressure, slow heart rate, and dizziness with the gel — some requiring hospitalization.
  • Rebound redness: Some patients using the topical gel experienced redness that returned worse than before after stopping treatment.
  • Allergic reactions: Allergic contact dermatitis can occur with the gel. Rare but serious immune reactions — including angioedema (deep swelling), throat tightening, and hives — have also been reported.
  • Do not apply gel to broken or irritated skin or in unapproved settings (e.g., after laser procedures).
🔀What it interacts with▾

Brimonidine can interact with several types of medications — tell your prescriber and pharmacist about everything you take.

  • MAO inhibitors (e.g., phenelzine, selegiline): must not be used with brimonidine eye drops — can dangerously amplify side effects including very low blood pressure. MAO inhibitors are a contraindication for the ophthalmic solution.
  • Blood pressure medications and cardiac glycosides (e.g., digoxin): brimonidine may add to their blood pressure-lowering effect, raising the risk of low blood pressure.
  • CNS depressants — including alcohol, sedatives, opioids, barbiturates, and anesthetics: may have an additive sedating or depressant effect when combined with brimonidine.
  • Tricyclic antidepressants (e.g., amitriptyline, nortriptyline): may interfere with brimonidine's eye pressure-lowering effect and affect how brimonidine is processed in the body.

This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.

📋Before taking it▾
  • Do not use brimonidine if you have ever had an allergic reaction to it or to any ingredient in the product.
  • Do not use the eye drops if you are currently taking a monoamine oxidase (MAO) inhibitor — this combination is contraindicated.
  • The ophthalmic solution is contraindicated in babies and infants under 2 years old.
  • Tell your doctor if you have depression, cerebral or coronary insufficiency (reduced blood flow to the brain or heart), Raynaud's phenomenon, orthostatic hypotension, thrombangiitis obliterans, scleroderma, or Sjögren's syndrome before using the topical gel.
  • Tell your doctor if you have severe, unstable, or uncontrolled cardiovascular disease before using the topical gel.
  • Pregnancy: There are no well-controlled human studies. Animal studies showed some risk at high doses. Use only if your doctor decides the benefit outweighs the potential risk.
  • Breastfeeding: Brimonidine eye drops are not recommended during breastfeeding — the drug may pass into breast milk and cause serious reactions (including breathing problems) in nursing infants.
  • Children aged 2–6: Extreme drowsiness is very common with the eye drops in this age group — discuss the risks carefully with your child's prescriber.
  • Older adults: No significant differences in safety or effectiveness have been observed compared to other adults.
🚑If you take too much▾

In adults, accidental ingestion of brimonidine has mainly been reported to cause low blood pressure (hypotension). In young children and infants, overdose — including from accidental swallowing of the topical gel or from the eye drops — can cause much more serious effects: extreme drowsiness, breathing problems, slow heart rate, low blood pressure, low body temperature, poor muscle tone, pallor, and coma. If you suspect an overdose or accidental ingestion — especially by a child — seek emergency medical care immediately. Treatment focuses on keeping the airway open and providing supportive care.

📡Pharmacodynamics — effects in the body▾

Brimonidine lowers intraocular (inside-the-eye) pressure by reducing fluid production in the eye and improving its outflow — peak effect occurs about two hours after an eye drop dose. Elevated eye pressure is a major risk factor for optic nerve damage and vision loss in glaucoma, so keeping it controlled matters. Importantly, at the doses used in eye drops, brimonidine has minimal effect on cardiovascular and pulmonary (heart and lung) parameters. On the skin, it narrows blood vessels to reduce visible facial redness.

🔬Pharmacokinetics — how your body processes it▾

When applied as an eye drop, brimonidine reaches peak blood levels about 1.7 hours after dosing and clears from the body with a systemic half-life of roughly 2 hours. It is about 29% bound to proteins in the blood. When applied as a topical gel to the face once daily, peak blood levels are very low and are highest around day 15, with no further accumulation after that. In both cases, brimonidine is extensively broken down (metabolized) by the liver, and most of the drug and its breakdown products leave the body through the urine.

📦How to store it▾

Store at 20°C to 25°C (68°F to 77°F) .

📄 Written from Brimonidine’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →

🩺 Pharmacist Counseling Corner

Quick, plain-English answers to the questions patients ask most about Brimonidine — the kind of thing our pharmacy team would talk through with you at the counter.

I have both glaucoma drops and the rosacea gel — are they basically the same thing? ▾
They contain the same active ingredient — brimonidine — but they're very different products. The eye drops are specifically formulated for use in the eye to lower pressure, while the gel is made for the skin to reduce facial redness. Never put the gel in your eyes or use the eye drops on your skin. Each product is designed for a specific purpose, and the concentrations and formulations are different.
My facial redness seems worse some days after I use the gel — is that normal? ▾
It can happen, and it's worth knowing about. Some people experience flushing or a temporary increase in redness a few hours after applying the gel — the redness-reducing effect can wear off before the next daily dose. There are also reports of a 'rebound' effect where redness returns worse than before when the gel is stopped. If you're noticing a pattern of worsening redness, let your doctor know — don't just stop the gel abruptly without talking to them first.
My child is 4 years old and has been prescribed the eye drops for glaucoma. Should I be worried about drowsiness? ▾
Yes — drowsiness is a real concern to watch for in young children. Clinical studies found that the majority of children between ages 2 and 6 experienced significant drowsiness with brimonidine eye drops. It's important to monitor your child closely, especially around activities that require alertness. If the sleepiness seems extreme or hard to wake them from, contact your doctor right away. Your prescriber is aware of this risk and has weighed the benefits — but keep them updated on how your child is responding.
Is it safe to use the rosacea gel if I have heart problems? ▾
It depends on how serious your heart condition is. Brimonidine can lower blood pressure, and the topical gel should be used with caution — or possibly avoided — in people with severe, unstable, or uncontrolled heart or cardiovascular disease. There have been postmarketing reports of low blood pressure, slow heart rate, and dizziness with the gel. Be upfront with your prescriber about your heart history so they can decide if it's appropriate for you.
Can I use the rosacea gel around my kids? ▾
You need to be very careful. Two young children in a clinical trial became seriously ill after accidentally ingesting the gel — they experienced breathing emergencies and were hospitalized. Store the gel completely out of reach of children, wash your hands right after applying it, and make sure children don't touch treated areas. If any child accidentally gets into it, treat it as an emergency and call 911 or poison control immediately.
Are there any medications I absolutely cannot take with brimonidine? ▾
Yes — MAO inhibitors are a hard stop with brimonidine eye drops. These are a class of older antidepressants (like phenelzine or selegiline also used in Parkinson's), and combining them with brimonidine can cause dangerous drops in blood pressure. Beyond that, be sure to tell your doctor about any blood pressure medications, sedatives, opioids, alcohol use, or tricyclic antidepressants — these can all interact with brimonidine in ways that need to be managed carefully.
Is Brimonidine available over the counter? ▾
Both — Brimonidine is sold both over the counter and by prescription, according to its FDA labeling. Lower strengths or certain forms are often available without a prescription, while higher strengths or specialized forms still require one. Ask your pharmacist which version is right for you.
When was Brimonidine first available? ▾
Brimonidine has been available in the United States since at least 1996, based on FDA approval history (Drugs@FDA) and product marketing records.
Who makes Brimonidine? ▾
Brimonidine is supplied by 37 manufacturers listed in the FDA NDC Directory, including Somerset Therapeutics, LLC, Allergan, Inc., Bausch & Lomb Incorporated.

💬 Answers drafted from Brimonidine’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →

🧰 Keep exploring

🌿Drug & Supplement CheckerBrimonidine vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Brimonidine NDCs & costs 🅰️Browse Drugs A–ZLook up any medication

💊 How Brimonidine comes

Brimonidine is available in 3 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Eye drops

In the eye
Brands Alphagan P Lumify Preservative Free Eye Drops LUMIFY Redness Reliever Eye Drops
How this form is used
What it may be used for
  • Alphagan P is used to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
  • Brimonidine Tartrate Ophthalmic Solution is used to lower elevated eye pressure in open-angle glaucoma or ocular hypertension
  • LUMIFY Redness Reliever Eye Drops and Lumify Preservative Free Eye Drops are used to relieve eye redness caused by minor eye irritations
Important instructions
  • Alphagan P: instill one drop in the affected eye(s) three times daily, approximately 8 hours apart
  • LUMIFY Redness Reliever Eye Drops: instill 1 drop in the affected eye(s) every 6–8 hours; do not use more than 4 times daily
  • Lumify Preservative Free Eye Drops: twist tab off to open the single-use vial, instill 1 drop, then discard the vial immediately — do not reuse; do not use more than 4 times daily
  • For all eye drops: remove contact lenses before use; wait at least 10 minutes before reinserting lenses; if using more than one eye drop product, wait at least 5 minutes between products
Available strengths 5 strengths
0.25 mg/mL 1 mg/mL 1.5 mg/mL 2 mg/mg 2 mg/mL
63 FDA-listed product records ⓘ

Topical cream, ointment or gel

On the skin
Brands Mirvaso
How this form is used
What it may be used for
  • Mirvaso topical gel is indicated for the treatment of persistent facial redness (erythema) of rosacea in adults 18 years of age and older
  • Brimonidine topical gel 0.33% is indicated for the treatment of persistent facial erythema of rosacea in adults 18 years of age and older
Important instructions
  • Mirvaso: apply a pea-sized amount once daily to each of five facial areas — central forehead, chin, nose, and each cheek — as a smooth, even thin layer; avoid the eyes and lips
  • Brimonidine topical gel: apply a pea-sized amount once daily to each of the five facial areas — forehead, chin, nose, and each cheek — avoiding eyes and lips
  • Wash hands immediately after applying the gel
  • For topical use on the face only — not for oral, ophthalmic, or intravaginal use; do not apply to irritated skin or open wounds
Available strengths 1 strength
5 mg/g
6 FDA-listed product records ⓘ

Oral solution

By mouth
Available strengths 1 strength
0.25 mg/mL
2 FDA-listed product records ⓘ

📊 Brimonidine across the U.S. market

How Brimonidine appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

3
Dose forms ⓘ
37
Manufacturers
7
Brand names
94
FDA-listed product records ⓘ
1996
First marketed ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Powder (23) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

Somerset Therapeutics, LLC13%
Allergan, Inc.9%
Bausch & Lomb Incorporated7%
Lifestar Pharma LLC6%
Pacific Pharma, Inc.5%
Apotex Corp.5%
Other makers54%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

📈 How widely Brimonidine is used

A general measure of how commonly Brimonidine is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Brimonidine is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

258,429
Medicaid prescriptions filled (Q1–Q4 2025)
$17.4M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Brimonidine prescribed? Of the 1,596 medications we measure, Brimonidine ranks #350 by Medicaid prescriptions — more than 78% of them.

Where Brimonidine ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #350 of 1,596
#345 Levonorgestrel 262,844 Rx #346 Nabumetone 262,800 Rx #347 Evolocumab Injection 262,375 Rx #348 Dorzolamide / Timolol 260,759 Rx #349 Dorzolamide and Timolo... 259,157 Rx #350 Brimonidine 258,429 Rx #351 Morphine Injection 257,677 Rx #352 Brimonidine Ophthalmic 257,228 Rx #353 Triprolidine 256,126 Rx #354 Minocycline 255,328 Rx #355 Epoetin Alfa, Injectio... 255,197 Rx

Utilization by Brimonidine product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 2 mg/mL ophthalmic solution is the most-dispensed Brimonidine product — about 80% of these Medicaid prescriptions.

brimonidine tartrate 2 MG/ML Ophthalmic Solution Most dispensed

206,649 Medicaid prescriptions (Q1–Q4 2025) 80% of Brimonidine prescriptions shown $2.5M gross reimbursement (before rebates) ≈ $12 per prescription (gross)

Summed across the 11 of 26 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 861200

brimonidine tartrate 1 MG/ML Ophthalmic Solution

25,973 Medicaid prescriptions (Q1–Q4 2025) 10% of Brimonidine prescriptions shown $7.7M gross reimbursement (before rebates) ≈ $295 per prescription (gross)

Summed across the 10 of 33 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 861204

brimonidine tartrate 1.5 MG/ML Ophthalmic Solution

24,196 Medicaid prescriptions (Q1–Q4 2025) 9% of Brimonidine prescriptions shown $6.7M gross reimbursement (before rebates) ≈ $277 per prescription (gross)

Summed across the 12 of 19 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 861208

brimonidine 0.0033 MG/MG Topical Gel

1,201 Medicaid prescriptions (Q1–Q4 2025) <1% of Brimonidine prescriptions shown $504,747 gross reimbursement (before rebates) ≈ $420 per prescription (gross)

Summed across the 1 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1437707

brimonidine tartrate 0.25 MG/ML Ophthalmic Solution

410 Medicaid prescriptions (Q1–Q4 2025) <1% of Brimonidine prescriptions shown $8,537 gross reimbursement (before rebates) ≈ $21 per prescription (gross)

Summed across the 2 of 15 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1999016

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Brimonidine, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 36 of 100 listed Brimonidine NDCs with Medicaid activity.

🔍 Compare Brimonidine products

A representative set of FDA-listed product records for Brimonidine — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 94 of 94 products — FDA National Drug Code Directory. See every product, package size and price: browse all 94 Brimonidine NDCs →

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Brimonidine RxCUI 134615 2 dose forms · 5 strengths
  2. Dose form (SCDF) Topical Gel RxCUI 1436952 In current FDA listings
    Clinical drug / strength (SCD) 0.0033 MG/MG RxCUI 1437707

Look up RxCUI 134615 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

🏷️ Sold under these brand names

Mirvaso Lumify Alphagan Alphagan P LUMIFY Redness Reliever Eye Drops Lumify Preservative Free Eye Drops

🏭 Manufacturers & labelers

Somerset Therapeutics, LLC 12 Allergan, Inc. 8 Bausch & Lomb Incorporated 7 Lifestar Pharma LLC 6 Pacific Pharma, Inc. 5 Apotex Corp. 5 Sandoz Inc 5 A-S Medication Solutions 4 Micro Labs Limited 3 Bryant Ranch Prepack 3 Galderma Laboratories, L.P. 3 Darmerica, Llc 2 Laurus Labs Limited 2 Padagis Israel Pharmaceuticals Ltd 2 Indoco Remedies Limited 2 Florida Pharmaceutical Products, LLC 2 Professional Compounding Centers of America 2 C-squared Pharma Limited 2 Piramal Healthcare (Canada) Limited 1 Piramal Pharma Limited 1 Gland Pharma Limited 1 Siegfried Grafton, Inc. 1 Symed Labs Limited 1 Unichem Laboratories Limited, India 1

…and 13 more on the FDA NDC directory.

RxNorm drug class

Brimonidine belongs to the alpha-Adrenergic Agonist class.

Pharmacologic class alpha-Adrenergic Agonist
Drug family (ATC) Other dermatologicals, Sympathomimetics in glaucoma therapy, Sympathomimetics used as decongestants
How it works Adrenergic alpha-Agonists

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

🔬 Where this comes from

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Nov 24, 2025
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Brimonidine.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Brimonidine after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
21
NDC products indexed
94
Distinct labelers/manufacturers represented
37
Linked representative label ⓘ
Sandoz Inc
Linked label effective
Nov 24, 2025
Composite sections available
23
Linked SPL Set ID
b1e7ebd4-d0d2-40a5-aa11-5f68bc5972bd
Linked SPL Document ID
6a98ed35-7065-4099-aefc-6d22e674ef55
Open the linked representative label on DailyMed ↗

How we combine label and product data

HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 21 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.

For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Sandoz Inc is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.

This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.